MedicalResearch: What is the background for this study? What are the main findings?
Prof. Hu: Triple-negative breast cancer (TNBC) is associated with higher rates of recurrence, shorter disease free survival, and poorer overall survival. Molecular targeting agents tried against Triple-negative breast cancer have nearly all failed. TNBC, concordant with BRCA-associated and basal-like breast cancer, has abnormal DNA repair and genome-wide instability, supporting the use of DNA-damaging agents such as platinum. However, platinum monotherapy is not very potent, combination with other agents, such as gemcitabine has a synergistic effect.
The GP regimen could be an alternative or even preferential first-line doublet chemotherapy strategy for patients with mTNBC.
MedicalResearch: What should clinicians and patients take away from your report?
- Cisplatin plus gemcitabine is one more option. Our study provides evidence for the establishment of an effective, non-anthracycline and non-taxane combination regimen for patients with triple-negative breast cancer.
- It is a safe approach if doctors combine our data and all other data from different sorts of cancer patients exposed to the doublet.
- Although cisplatin-related hydration can increase hospital stay and may not be cost-effective, it is still acceptable considering its efficacy. It is more applicable in countries, like China, where nearly all intravenous chemotherapy is delivered in wards, not in outpatient clinics.
MedicalResearch: What recommendations do you have for future research as a result of this study?
- Translational studies should be done to identify patients who really benefit from platinums.
- NCCN guideline group recommends gemcitabine plus carboplatin, it is very important to determine which one will be the winner in Triple-negative breast cancer.
- To improve the safety profile, hydration with more focus on electrolyte balance and use of new standard anti-emetic measures.
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
MedicalResearch.com Interview with: Prof Xi-Chun Hu, Department of Oncology (2015). Possible New Chemotherapy Regimen For Triple-Negative Breast Cancer